Abstract
The benefit of cholesterol-lowering drug therapy in patients with existing coronary heart disease (CHD) is well established through clinical trials. Prevention of recurrent coronary morbidity and mortality in CHD patients is called secondary prevention. In contrast, primary prevention is delaying or preventing altogether new-onset-CHD. There are three categories of primary prevention: high-risk, moderate-risk, and long-term (life-time). A recent clinical trial has documented benefit of cholesterol-lowering drugs for prevention of coronary morbidity and mortality and total mortality in hyper-cholesterolemic, middle-aged men. This trial lends support for including aggressive cholesterol reduction in high-risk primary prevention. However, for such therapy to be cost effective at present-day prices of cholesterol-lowering drugs, only those patients in the higher ranges of risk can be selected for treatment. This leaves a large number of people at moderately high risk for premature CHD because of high cholesterol levels. These persons deserve increased professional attention to risk reduction. In general the nondrug approach is indicated. The latter approach includes eliminating other risk factors, e.g. cigarette smoking and hyperte...Continue Reading
Citations
Mar 21, 1998·Current Opinion in Lipidology·F W Hanna
Jun 1, 2012·Lipids in Health and Disease·Lin MiaoWei-Xiong Lin
Jul 28, 2011·Chemical Biology & Drug Design·Qun HaoWeicheng Zhou
Jul 9, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·George I Gorodeski
Feb 27, 1999·Preventive Medicine·R M MerrillE J Feuer
Feb 5, 2004·Journal of the American Dietetic Association·Wendy D PavlovichEric B Bass
Mar 26, 2002·Journal of Occupational and Environmental Medicine·Cheryl PegusJoseph Menzin
Apr 20, 1999·Circulation·C NapoliW Palinski
Mar 2, 1999·Circulation·A M Gotto, S M Grundy
Dec 30, 1998·Current Opinion in Lipidology·A D Marais
Jun 21, 2003·The American Journal of Clinical Nutrition·Jason M R GillChris J Packard
Sep 5, 2019·Current Computer-aided Drug Design·David Mary RajatheiSamuel Selvaraj
Dec 13, 2007·Journal of Medicinal Chemistry·Jeffrey A PfefferkornBradley D Tait
Apr 2, 2010·Journal of Medicinal Chemistry·Shigehiro AsanoYoshihide Ueno
Jun 15, 2007·Bioorganic & Medicinal Chemistry·Larry D BrattonPaul C Unangst